← SynDRA
MK-5108
SynDRA canonical compound SYN0038334 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
| Primary target(s) | AURKB |
| Mechanism of action | Aurora kinase inhibitor |
All known targets
Mechanisms of action (all sources)
- aurora kinase inhibitor
- AURKA INHIBITOR
- Serine/threonine-protein kinase Aurora-A inhibitor
- AURKB INHIBITOR
Cross-references
Synonyms
- MK 5108
- MK5108
- VX-689
- VX 689
- MK-5108 (VX-689)
- UNII-H8J407531S
- VX689
- CHEMBL3600873
- H8J407531S
- 4-(3-chloro-2-fluorophenoxy)-1-[[6-(1,3-thiazol-2-ylamino)pyridin-2-yl]methyl]cyclohexane-1-carboxylic acid
- 4-(3-Chloranyl-2-Fluoranyl-Phenoxy)-1-[[6-(1,3-Thiazol-2-Ylamino)pyridin-2-Yl]methyl]cyclohexane-1-Carboxylic Acid
- (1r,4r)-4-(3-chloro-2-fluorophenoxy)-1-((6-(thiazol-2-ylamino)pyridin-2-yl)methyl)cyclohexane-1-carboxylic acid
- Cyclohexanecarboxylic acid,
- MK-5108/VX-689
- 4-(3-chloranyl-2-fluoranyl-phenoxy)-1-[[6-(1,3-thiazol-2-ylamino)pyridin-2-yl]methyl]cyclohexane-1-carboxylic acid
Look up MK-5108 in the interactive SynDRA portal →